home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

2.941 -0.069 (-2.29%)

Streaming Delayed Price Updated: 1:48 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

3 Monster Stocks to Hold for the Next 10 Years ↗

April 23, 2025

They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth.

Via The Motley Fool

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

April 22, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? ↗

April 18, 2025

Via The Motley Fool

Why Recursion Pharmaceuticals Stock Is Sinking Today ↗

March 10, 2025

Via The Motley Fool

Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News ↗

April 15, 2025

Via Stocktwits

Topics Animal Testing Artificial Intelligence Stocks

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing ↗

April 14, 2025

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Via Benzinga

Topics Animal Testing

Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX ↗

April 13, 2025

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Via Stocktwits

Topics Animal Testing

These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗

April 13, 2025

Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

Via Benzinga

The market is filled with gapping stocks in Friday's session. ↗

April 11, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Why Recursion Pharmaceuticals Stock Is Skyrocketing Today ↗

April 11, 2025

Via The Motley Fool

Topics Animal Testing Artificial Intelligence

Recursion Pharmaceuticals Shares Are Up Today: what's Going On? ↗

April 11, 2025

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced a significant policy change that could reshape the drug...

Via Benzinga

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗

April 11, 2025

Via Benzinga

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗

April 11, 2025

Via Benzinga

Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated ↗

April 10, 2025

Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery.

Via Stocktwits

Topics Animal Testing Artificial Intelligence

Wondering what's happening in today's after-hours session? ↗

April 10, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements ↗

April 10, 2025

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing...

Via Benzinga

Topics Animal Testing

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 10, 2025

Via Benzinga

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

April 09, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

April 08, 2025

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors

From Recursion Pharmaceuticals

Via GlobeNewswire

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗

April 03, 2025

Via The Motley Fool

Topics Bankruptcy Economy World Trade

Recursion to Participate in Upcoming Investor Conference

April 01, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗

March 31, 2025

Via The Motley Fool

Topics Government World Trade

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? ↗

March 30, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks ↗

March 30, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock ↗

March 10, 2025

Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."

Via Benzinga

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

March 18, 2025

Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.

From Recursion Pharmaceuticals

Via GlobeNewswire

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? ↗

March 08, 2025

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip ↗

March 08, 2025

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.

Via Benzinga

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today ↗

March 07, 2025

Via The Motley Fool

This Biotech Stock Could Be the Best Investment of the Decade ↗

March 07, 2025

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com